Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)

Trial Profile

Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Belimumab (Primary) ; Cyclophosphamide; Diphenhydramine; Methylprednisolone; Paracetamol; Prednisone; Rituximab
  • Indications Lupus nephritis
  • Focus Adverse reactions
  • Acronyms CALIBRATE
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 03 Feb 2016 Planned End Date changed from 1 Jan 2019 to 1 Jun 2019, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top